GSK plc (GSK) Financial Statements

Executive TeamFinancials
Shareholders

GSK financial statements at a glance

GSK reported revenue of 32.67 billion GBP for fiscal year 2025 (ended December 31, 2025), up 4.1% from fiscal year 2024. Net income was 5.72 billion GBP, a net margin of 17.5%, and diluted earnings per share were 1.39 GBP.

At the end of fiscal year 2025 it had total assets of 61.12 billion GBP, total liabilities of 45.16 billion GBP and shareholders' equity of 16.38 billion GBP, with cash and short-term investments of 3.16 billion GBP and total debt of 17.72 billion GBP.

Its operations brought in 7.74 billion GBP of cash; capital spending was 2.99 billion GBP, leaving free cash flow of 4.76 billion GBP.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in GBP; latest fiscal year ended December 31, 2025.

GSK logo

GSK plc

GSKUnited Kingdom
Healthcare
GBP (Local)

Income Statement

Annual • GBP

Total Revenue
32.67B
Prev Year: 31.38B
YoY: +4.1%
Operating Revenue
32.67B
Prev Year: 31.38B
YoY: +4.1%
Total Unusual Items Excluding Goodwill
-305.00M
Prev Year: -1.46B
YoY: +79.1%
Total Unusual Items
-305.00M
Prev Year: -1.46B
YoY: +79.1%
Normalized EBITDA
10.71B
Prev Year: 8.13B
YoY: +31.7%
Tax Rate for Calcs
0.15
Prev Year: 0
Tax Effect of Unusual Items
-45.83M
Prev Year: -220.31M
YoY: +79.2%
Total Operating Income as Reported
7.93B
Prev Year: 4.02B
YoY: +97.3%
Noncontrolling Interests
-573.00M
Prev Year: -376.00M
YoY: -52.4%
Total Other Finance Cost
2.00M
Prev Year: 23.00M
YoY: -91.3%
Cost of Revenue
9.02B
Prev Year: 9.05B
YoY: -0.3%
Gross Profit
23.65B
Prev Year: 22.33B
YoY: +5.9%
Operating Expense
15.31B
Prev Year: 16.79B
YoY: -8.8%
Selling General and Administrative
9.09B
Prev Year: 11.02B
YoY: -17.5%
General and Administrative Expense
9.09B
Prev Year: 11.02B
YoY: -17.5%
Research and Development
7.53B
Prev Year: 6.40B
YoY: +17.6%
Operating Income
8.34B
Prev Year: 5.54B
YoY: +50.5%
Net Non Operating Interest Income Expense
-633.00M
Prev Year: -603.00M
YoY: -5.0%
Non-operating Interest Income
56.00M
Prev Year: 60.00M
YoY: -6.7%
Non-operating Interest Expense
687.00M
Prev Year: 640.00M
YoY: +7.3%
Special Income Charges
-813.00M
Restructuring and Mergers Acquisition
581.00M
Other Special Charges
232.00M
Pre-tax Income
7.40B
Prev Year: 3.48B
YoY: +112.9%
Provision for Income Taxes
1.11B
Prev Year: 526.00M
YoY: +111.4%
Net Income Common Stockholders
5.72B
Prev Year: 2.58B
YoY: +122.0%
Net Income
5.72B
Prev Year: 2.58B
YoY: +122.0%
Net Income Including Non-Controlling Interests
6.29B
Prev Year: 2.95B
YoY: +113.1%
Net Income from Continuing Operations
6.29B
Prev Year: 2.95B
YoY: +113.1%
Diluted NI Available to Com Stockholders
5.72B
Prev Year: 2.58B
YoY: +122.0%
Basic EPS
1.411
Prev Year: 0.63
YoY: +124.0%
Diluted EPS
1.388
Prev Year: 0.62
YoY: +123.9%
Weighted Average Shares (basic)
4.05B
Prev Year: 4.08B
YoY: -0.6%
Weighted Average Shares (diluted)
4.12B
Prev Year: 4.14B
YoY: -0.6%
Total Expenses
24.33B
Prev Year: 25.83B
YoY: -5.8%
Rent Expense (supplemental)
-
Prev Year: 30.00M
Net Income from Continuing and Discontinued Operation
5.72B
Prev Year: 2.58B
YoY: +122.0%
Normalized Income
5.98B
Prev Year: 3.81B
YoY: +56.7%
Interest Income
56.00M
Prev Year: 60.00M
YoY: -6.7%
Interest Expense
687.00M
Prev Year: 640.00M
YoY: +7.3%
Net Interest Income
-633.00M
Prev Year: -603.00M
YoY: -5.0%
EBIT
8.09B
Prev Year: 4.12B
YoY: +96.5%
EBITDA
10.40B
Prev Year: 6.67B
YoY: +56.0%
Reconciled Cost of Revenue
9.02B
Prev Year: 9.05B
YoY: -0.3%
Reconciled Depreciation
2.31B
Prev Year: 2.55B
YoY: -9.3%
Net Income from Continuing Operation Net Minority Interest
5.72B
Prev Year: 2.58B
YoY: +122.0%
Values in GBP

GSK key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue32.7B GBP31.4B GBP30.3B GBP29.3B GBP24.7B GBP
Gross profit23.7B GBP22.3B GBP21.8B GBP19.8B GBP16.5B GBP
Operating income8.3B GBP5.5B GBP7.3B GBP6.7B GBP4.9B GBP
Net income5.7B GBP2.6B GBP4.9B GBP15.0B GBP4.4B GBP
Diluted EPS1.39 GBP0.62 GBP1.20 GBP3.66 GBP1.08 GBP
Total assets61.1B GBP59.5B GBP59.0B GBP60.1B GBP79.1B GBP
Total liabilities45.2B GBP46.4B GBP46.2B GBP50.1B GBP57.8B GBP
Shareholders' equity16.4B GBP13.7B GBP13.3B GBP10.6B GBP15.1B GBP
Cash and short-term investments3.2B GBP3.7B GBP5.0B GBP7.7B GBP4.1B GBP
Total debt17.7B GBP17.0B GBP18.0B GBP21.0B GBP24.2B GBP
Operating cash flow7.7B GBP6.6B GBP6.8B GBP7.4B GBP8.0B GBP
Capital spending3.0B GBP3.0B GBP2.3B GBP2.3B GBP2.7B GBP
Free cash flow4.8B GBP3.6B GBP4.4B GBP5.1B GBP5.3B GBP

In GBP. Fiscal years as reported by the company; statements on this page go back to fiscal year 2014.

Questions and answers

What was GSK's revenue in fiscal year 2025?

32.67 billion GBP, up 4.1% from 31.38 billion GBP in fiscal year 2024.

How much profit does GSK make?

GSK reported net income of 5.72 billion GBP for fiscal year 2025 (17.5% of revenue); operating income was 8.34 billion GBP.

How much cash and debt does GSK have?

At the end of fiscal year 2025: cash and short-term investments of 3.16 billion GBP and total debt of 17.72 billion GBP.

What is GSK's free cash flow?

4.76 billion GBP in fiscal year 2025 (operating cash flow of 7.74 billion GBP minus capital spending of 2.99 billion GBP).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube